Cristin-prosjekt-ID: 631282
Registrert av: REK Sist endret: 19. desember 2018 00:00 Sist endret av: REK

Cristin-prosjekt-ID: 631282
Registrert av: REK Sist endret: 19. desember 2018 00:00 Sist endret av: REK
Prosjekt

Biomarkører for tuberkulose diagnostikk og behandlingseffekt

prosjektleder

Harleen Grewal
ved Universitetet i Bergen

prosjekteier / koordinerende forskningsansvarlig enhet

  • Universitetet i Bergen

Godkjenninger

  • Regionale komitéer for medisinsk og helsefaglig forskningsetikk (REK) - 2018/1614

Kategorier

Prosjektkategori

  • Bidragsprosjekt

Helseprosjekttype

Annet klinisk behandlingsstudium

Tidsramme

Avsluttet
Start: 15. september 2018 Slutt: 7. oktober 2020

Beskrivelse Beskrivelse

Tittel

Biomarkører for tuberkulose diagnostikk og behandlingseffekt

Populærvitenskapelig sammendrag

Two billion people are infected with M. tuberculosis globally. The ability to identify correlates of risk that predict the progression to active TB could lead to targeted preventive treatment for TB, and targeted enrollment of at-risk individuals into efficacy trials of new TB vaccines and drugs. Further, elucidating the natural protective immunity to M. tuberculosis infection (correlates of protection from infection) is important for novel TB vaccines as well as for host-directed immune therapies. Our ultimate aim is to contribute to tests with diagnostic, predictive and prognostic utility, applicable across diverse populations and age groups, in order to break the chain of TB transmission. Assays based on peripheral whole blood (WB) are attractive, since it is more accessible for diagnosis than respiratory or tissue samples, particularly in children. The project will identify biomarkers based on transcriptomes in WB from samples collected in collaborative TB studies in India.

Tittel

Biomarkører for tuberkulose diagnostikk og behandlingseffekt

Populærvitenskapelig sammendrag

Two billion people are infected with M. tuberculosis globally. The ability to identify correlates of risk that predict the progression to active TB could lead to targeted preventive treatment for TB, and targeted enrollment of at-risk individuals into efficacy trials of new TB vaccines and drugs. Further, elucidating the natural protective immunity to M. tuberculosis infection (correlates of protection from infection) is important for novel TB vaccines as well as for host-directed immune therapies. Our ultimate aim is to contribute to tests with diagnostic, predictive and prognostic utility, applicable across diverse populations and age groups, in order to break the chain of TB transmission. Assays based on peripheral whole blood (WB) are attractive, since it is more accessible for diagnosis than respiratory or tissue samples, particularly in children. The project will identify biomarkers based on transcriptomes in WB from samples collected in collaborative TB studies in India.

prosjektdeltakere

prosjektleder

Harleen Grewal

  • Tilknyttet:
    Prosjektleder
    ved Universitetet i Bergen

Aparna Mukherjee

  • Tilknyttet:
    Prosjektdeltaker
    ved All India Institute of Medical Sciences

Tore Elling Ulvestad

  • Tilknyttet:
    Prosjektdeltaker
    ved Universitetet i Bergen

Rakesh Lodha

  • Tilknyttet:
    Prosjektdeltaker
    ved All India Institute of Medical Sciences

Sushil Kabra

  • Tilknyttet:
    Prosjektdeltaker
    ved All India Institute of Medical Sciences
1 - 5 av 5